Letters to the Editor

IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma

Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Institute of Oncology Research, Bellinzona
Lymphoma Unit,Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan
Department of Internal Medicine I, Division of Oncology, Medical University Vienna, Vienna
Department of Hematology, Hospital Clínic de Barcelona, Barcelona
Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Milan
Department of Hematology, Institut Català d’Oncologia, Hospital Duran i Reynals, IDIBELL, Barcelona
Division of Hematology, AO Spedali Civili di Brescia, Brescia
Hematology Unit, AO Papardo, Messina
Department of Haematology Ospedale di Circolo di Varese, Varese
Department of Clinical Hematology Hospital del Mar, Barcelona
Department of Medicine, Section of Hematology, University of Verona, Verona
Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona
Institute of Oncology Research, Bellinzona
Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Institute of Oncology Research, Bellinzona, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Bellinzona
Lymphoma Unit,Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan
Department of Internal Medicine I, Division of Oncology, Medical University Vienna, Vienna
Haematologica Early view Dec 22, 2022 https://doi.org/10.3324/haematol.2022.281963